Cancer Mechanisms and Emerging Therapies.

Pharmaceutics

Medical Oncology Unit, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, 21100 Varese, Italy.

Published: July 2021

Over the last decades, cancer has become one of the most relevant health issues at a worldwide level [...].

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308996PMC
http://dx.doi.org/10.3390/pharmaceutics13071045DOI Listing

Publication Analysis

Top Keywords

cancer mechanisms
4
mechanisms emerging
4
emerging therapies
4
therapies decades
4
decades cancer
4
cancer relevant
4
relevant health
4
health issues
4
issues worldwide
4
worldwide level
4

Similar Publications

The regulation of cell physiology depends largely upon interactions of functionally distinct proteins and cellular components. These interactions may be transient or long-lived, but often affect protein motion. Measurement of protein dynamics within a cellular environment, particularly while perturbing protein function with small molecules, may enable dissection of key interactions and facilitate drug discovery; however, current approaches are limited by throughput with respect to data acquisition and analysis.

View Article and Find Full Text PDF

Purpose: Long noncoding RNAs (lncRNAs) play crucial regulatory roles in the tumorigenesis and progression of various cancers. However, the functional roles of lncRNAs in papillary thyroid cancer (PTC) remain unclear. In this study, we investigated the functional role of the lncRNA FAM111A-DT in PTC progression and the underlying mechanisms.

View Article and Find Full Text PDF

Background: Sex hormone-binding globulin (SHBG) plays a critical role in regulating androgen bioavailability and has been hypothesized to influence prostate cancer risk, though existing evidence is inconsistent. This systematic review and meta-analysis aimed to evaluate the association between SHBG levels and prostate cancer risk.

Methods: A comprehensive search was conducted across PubMed, Embase, and Web of Science for studies published up to December 1, 2024.

View Article and Find Full Text PDF

Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.

Curr Oncol Rep

January 2025

Susan F. Smith Center for Women's Cancers, Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.

Purpose Of Review: In this review, we discuss evidence supporting the use of antibody-drug conjugates (ADCs) in breast cancer treatment, describe novel ADCs and combination regimens under development, and examine our current understanding of resistance mechanisms and biomarkers to guide ADC selection and sequencing.

Recent Findings: Three ADCs have proven benefit in patients with metastatic breast cancer: trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG). There are over two hundred investigational ADCs on the horizon, as pre-clinical studies work to identify novel ADC targets and structures.

View Article and Find Full Text PDF

Cancer remains one of the most formidable challenges in the medical field in this century, largely due to its poorly understood pathogenesis. Fortunately, recent advancements in the understanding of cancer pathogenesis have helped identify more therapeutic targets for improved treatment outcomes. The WNT signaling pathways are highly conserved cascades that participate in diverse physiological processes, such as embryonic development, tissue homeostasis, and tissue regeneration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!